The ZIO Service, a heart-monitoring device, which has been available in the United States of America since 2011 is now available in the UK.
The ZIO Service comprises the ZIO XT Patch, analysis and the ZIO Report. The ZIO XT patch is a non-invasive, water-resistant heart monitor that is easy to use and discrete to wear. It can be worn for up to 14 days – delivering high patient compliance and a higher diagnostic yield. The subsequent analysis looks at the heart beat data and a report is provided to the patient’s cardiologist.
The ZIO Service is backed by multiple peer-reviewed, published studies and is already recognised as the new standard of care for diagnosing atrial fibrillation (AF) and other cardiac arrhythmias in the United States. Since its launch in the USA in 2011 it has been used with over 250,000 patients. A recent study by Barrett et al showed a 57% greater diagnostic yield than the Holter monitor, primarily due to prolonged monitoring and that 4 out of 5 patients who had worn a Holter monitor for 24 hours, and a ZIO Patch for up to 14 days, preferred the ZIO Patch.
The UK’s National Institute for Health and Care Excellence (NICE) recently announced new guidelines to improve treatment for people with AF, the most common type of heart rhythm disturbance, and thus reduce the risk of stroke. According to NICE AF affects approximately 800,000 people in the UK and it is believed that another 250,000 people may be undiagnosed.
Martyn Dixon, Managing Director, CardioLogic Ltd commented: “The first step in providing patients with appropriate treatment for AF is to ensure they are properly diagnosed. Traditional monitoring techniques have been limited in their ability to detect cardiac arrhythmias because they do not capture enough information or for a long enough period of time. With its user-friendly biosensing technology and powerful analytics, the ZIO Service overcomes these limitations to improve diagnosis with the potential to improve outcomes for the growing number of people affected with this heart rhythm disorder”.
Word Count 338
Deborah Goodall firstname.lastname@example.org 07903 387143
Notes to Editors
Peer Reviewed Published Studies:
The American Journal of Medicine, Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring Barrett P., Komatireddy R., Haaser S. et al.
Pacing and Clinical Electrophysiology Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: A Pilot Study Rosenberg M., Samuel M., Thosani A., Zimetbaum P.
Western Journal of Emergency Medicine Ambulatory Cardiac Monitoring for Discharged Emergency Department Patients with Possible Cardiac Arrhythmias Schreiber Donald, MDCM et al.
Feasibility of Outpatient Ambulatory ECG Monitoring to Screen for Silent Atrial Fibrillation: Findings from the Screening Trial for Undiagnosed Atrial Fibrillation (STUDY-AF) Turakhia M., Ullal A., Than C. et al.
Comparative Effectiveness of 14-day Zio Patch-Based versus 24-hour Holter Ambulatory ECG Monitoring for Atrial Fibrillation: Insights from an Interrupted Time Series Analysis Miller J., Hoang D., Perino A. et al.
Impact of a Novel Ambulatory ECG Monitoring Technology on Service Parameters in an Urban Safety-Net Hospital Su G., Fought A., Chen A. et al.
About CardioLogic Ltd
Cardiologic ltd is a privately held cardiology business specialising in distributing and supporting cardiac rhythm management solutions. Focusing initially on atrial fibrillation (AF), Cardiologic has a vision of transforming the patient pathway towards a rapid comprehensive assessment of AF and other arrhythmias within the NHS. For more information, please visit www.cardiologic.co.uk
About iRhythm Technologies, Inc.
iRhythm is a privately held digital healthcare company that aspires to be the world leader in cardiac arrhythmia information. iRhythm develops and commercializes FDA-cleared solutions that integrate consumer-friendly biosensor technology, vast patient data, powerful analytics and medical expertise. Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com.
This press release was distributed by ResponseSource Press Release Wire on behalf of Cardiologic Ltd in the following categories: Medical & Pharmaceutical, for more information visit https://pressreleasewire.responsesource.com/about.